Short-Term Outcomes in Membranous Nephropathy: Insights from A Single Study Center
Abstract
To determine the short-term outcomes of membranous nephropathy (MN) in patients visiting outpatient department of nephrology, Bahawal Victoria Hospital, Bahawalpur.
Patients of either gender and any age, having renal biopsy proven MN, visiting outpatient department of nephrology between October 2021 to August 2024, and treated for a minimum duration of 6 months were analyzed. All of the patients underwent a systematic physical examination, and detailed information about their medical history was gathered. Patients were then subjected to necessary baseline investigations. Follow up visits were planned every month and final outcome was labeled after 6 months treatment.
In a total of 178 patients with MN, the mean age was 32.25±12.86 years. There were 117 (65.7%) male patients. The mean duration of symptoms was 7.80±13.04 months. Most frequent types of treatment advised were conservative and cyclical regimens used in 80 (44.9%), and 33 (18.5%) patients, respectively. Post-treatment, 74 (41.6%) patients had complete proteinuria remission, 93 (52.2%) partial remission, whereas 11 (6.2%) patients had nephrotic proteinuria progression. Post-treatment proteinuria status was having significant association with duration of symptoms (p=0.003), baseline proteinuria (p<0.001), baseline serum albumin (p=0.024), baseline progression risk score (p=0.001), and treatment types (p=0.001). Post-treatment, 134 (75.3%) patients did not report renal dysfunction.
This study emphasizes the importance of baseline parameters and treatment modalities in predicting and influencing post-treatment outcomes in MN, providing valuable insights for more targeted and effective patient care. Favorable short-term outcomes were reported in vast majority of patientswith membranous nephropathy.
How to Cite This Article
Khan R, Malik SI, Idrees MK, Abbass A, Riaz MT, Ali QM. Short-Term Outcomes in Membranous Nephropathy: Insights from A Single Study Center. J Pak Soc Intern Med. 2025;6(2):159–165. doi:10.70302/jpsim.v6i2.2530
Conflict of Interest
All authors declare no competing interests.
Funding
No specific funding was received for this research.
Funder information follows the Crossref Funder Registry standard.
References
- Gu Y, Xu H, Tang D. Mechanisms of Primary Membranous Nephropathy. Biomol. 2021;11(4):513.
- Ronco P, Debiec H. Molecular Pathogenesis of Membranous Nephropathy. Annu Rev Pathol. 2020;15:287-313.
- Peleg Y, Bomback AS, Canetta PA, Radhakrishnan J, Appel GB, Ahn W. Late relapses of membranous nephropathy: A case series. Kidney360. 2021;2(6):974-982. doi:10.34067/KID.0007712020 doi:10.34067/KID.0007712020
- Dantas M, Silva LBB, Pontes BTM, Dos Reis MA, de Lima PSN, Moysés Neto M. Membranous nephropathy. J Bras Nefrol. 2023;45(2):229-243.
- von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11(11):CD004293.
- Scolari F, Alberici F, Mescia F, Delbarba E, Trujillo H, Praga M, et al. Therapies for membranous nephropathy: A tale from the old and new millennia. Front Immunol. 2022;13:789713.
- Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Graca D, Esnault VLM, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous Nephropathy. Front Immunol. 2022;13:859419.
- Ponticelli C, Praga M, Moroni G. Calcineurin inhibitors in membranous nephropathy. Kidney Int Rep. 2021;6(10):2537-2539. doi:10.1016/j.ekir.2021.08.008 doi:10.1016/j.ekir.2021.08.008
- Hashmi AA, Hussain ZF, Edhi MM, Mumtaz S, Faridi N, Khan M. Insight to changing morphologic patterns of glomerulopathy in adult Pakistani patients: an institutional perspective. BMC Res Note. 2016;9(1):73.
- Kumar MKH, Sandhu J, Sandhu JS. Profile and primary treatment outcomes in membranous nephropathy. Saudi Med J. 2022;43 (9):1051-6
- He P, Zha Y, Liu J, Wang H, He L. Clinical outcomes of patients with primary membranous nephropathy and subnephrotic proteinuria. Front Med. 2021;8:737700.
- Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899-1904.
- Ram R, Guditi S, Kaligotla Venkata D. A 10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series. Ren Fail. 2015;37(3):452-5.
- Ramachandran R, Yadav AK, Kumar V, Pinnamaneni VST, Nada R, Ghosh R, et al. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2(4):610-6.
- Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009;24(10):3082-38.
- . Qin HZ, Liu L, Liang SS, Shi JS, Zheng CX, Hou Q, et al. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol 2017;18(1):2.
- Westermann L, Rottmann FA, Hug MJ, Staudacher DL, Wobser R, Arnold F, et al. Clinical covariates influencing clinical outcomes in primary membranous nephropathy. BMC Nephrol. 2023;24(1):235.
- Wang YN, Feng HY, Nie X, Zhang Y, Zou L, Li X, et al. Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy. Front Pharmacol. 2022;13:907108.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.